Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473.
- J. Holford, S. Sharp, B. Murrer, M. Abrams, L. Kèlland
- Biology, MedicineBritish Journal of Cancer
This new class of sterically hindered platinum compound, selected for clinical trial in 1997, may therefore elicit improved clinical response in intrinsically and acquired cisplatin-resistant tumours in the clinic.
ras mutation and platinum resistance in human ovarian carcinomas in vitro
Very little evidence was found to support Harvey‐ras activation as a factor which can either sensitize or confer resistance to cisplatin in human ovarian carcinoma cell lines.
Chemical, biochemical and pharmacological activity of the novel sterically hindered platinum co-ordination complex, cis-[amminedichloro(2-methylpyridine)] platinum(II) (AMD473).
AMD473 circumvents resistance in vitro in acquired cisplatin resistant human ovarian carcinoma (HOC) cell line models and was shown to form DNA interstrand cross-links (ICLs) in both naked pBR322 plasmid and SKOV-3 cellular DNA, although AMD473 formed ICLs at a much slower rate than cis platin.
Signal transduction pathways for B1 and B2 bradykinin receptors in bovine pulmonary artery endothelial cells.
Pharmacological evidence is provided for the existence of two distinct bradykinin receptor subtypes (B1 and B2) on CPAE cells, with no evidence for heterologous desensitization.
Mechanisms of drug resistance to the platinum complex ZD0473 in ovarian cancer cell lines.
- J. Holford, P. Beale, F. Boxall, S. Sharp, L. Kèlland
- Biology, MedicineEuropean journal of cancer
- 1 October 2000
Overexpression of metallothionein in A2780 cells by stable gene transfection resulted in protection from the growth-inhibitory effects of cadmium chloride and a range in protection with platinum drugs.
Circumvention of tumour resistance to the platinum-based anticancer drug cisplatin.
- J. Holford